
Springwell360 Launches 40 Under 40 Health Equity Trailblazers Recognition Program
The 40 Under 40 Health Equity Trailblazers program seeks to celebrate professionals who are working to improve outcomes in underrepresented and underserved communities. Each honoree will receive a plaque recognizing their achievements and commitment to health equity.
Founded by Dr. Nadine Spring, a public health professor and certified clinical research professional, SpringWell360 was established to address the absence of diversity in clinical trials that continues to hinder medical progress and perpetuate health equity gaps. The 40 Under 40 program represents the latest initiative in the company's mission to promote inclusivity and representation in clinical research.
The recognition program complements SpringWell360's existing portfolio of educational resources and services, which includes the recently published book "Mastering Clinical Research – Pathway to a Six-Figure Career," specialized training courses, one-on-one coaching, and the Health Equity Grant that awards $1,000 to support projects addressing healthcare disparities.
Applications are now open for the 40 Under 40 Health Equity Trailblazers program. Healthcare professionals, researchers, advocates, and leaders under 40 who are actively working to advance health equity are encouraged to apply through the SpringWell360 website.
About SpringWell360
SpringWell360 LLC is an organization dedicated to transforming the clinical research landscape through education, training, and advocacy. Founded by Dr. Nadine Spring, a public health professor and certified clinical research professional, the company offers programs, resources, and services designed to equip professionals and organizations with the tools to excel in clinical research while promoting inclusivity and representation. SpringWell360's initiatives include publications, courses and coaching, grants, recognition programs, and site training partnerships focused on Good Clinical Practice (GCP) training and representation in clinical trials.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Pepeto Presale Exceeds $6.93 Million Staking And Exchange Demo Released
- Citadel Launches Suiball, The First Sui-Native Hardware Wallet
- Luminadata Unveils GAAP & SOX-Trained AI Agents Achieving 99.8% Reconciliation Accuracy
- Tradesta Becomes The First Perpetuals Exchange To Launch Equities On Avalanche
- Thinkmarkets Adds Synthetic Indices To Its Product Offering
- Edgen Launches Multi‐Agent Intelligence Upgrade To Unify Crypto And Equity Analysis
Comments
No comment